Study of apraglutide for short bowel syndrome with intestinal failure
Part of Digestive system clinical trials.
This study tests a new medicine called apraglutide, given as a shot, to see if it can help adults with short bowel syndrome and intestinal failure reduce their need for intravenous nutrition (parenteral support). The study compares apraglutide to a placebo (a shot with no medicine) to check if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have short bowel syndrome with intestinal failure, and have had surgery that removed part of your small intestine. The remaining small intestine should be at least 10 cm but less than 200 cm from a specific point.
- You must need intravenous nutrition (parenteral support) at least 3 days per week.
- Your body weight must give a BMI between 18.5 and 30 (check with your doctor).
- If you have a stoma (jejunostomy or ileostomy), your last surgery must have been at least 6 months ago. If you have your colon in continuity, it must be at least 12 months since your last surgery.
- You must be willing to follow a set daily drinking plan and collect your urine for 48-hour periods during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medicine teduglutide in children (ages 1–17) with Short Bowel Syndrome who need IV nutrition. The goal is to see if teduglutide can help them reduce or stop IV nutrition.
This study looks at short bowel syndrome in children who have had intestinal surgery. It may help doctors understand how to better treat this condition.
This study looks at how bacteria in your gut help your digestive system adapt after short bowel surgery. Researchers will track your microbiota (the trillions of bacteria in your gut) to understand how it changes and helps your body adjust to having less small intestine.
This trial tests a new medication called glepaglutide to see if it can help people with short bowel syndrome (SBS) who need IV nutrition or fluids at least 3 days a week. The goal is to reduce or even stop the need for these IV treatments.
This Phase 2 study tests whether sonefpeglutide is safe and how the body handles it (pharmacokinetics) in people with short bowel syndrome. It may help people who still need nutrition through a tube because their intestinal condition is stable.
This study tests a medicine called teduglutide for adults in China with short bowel syndrome who need long-term IV nutrition or fluids (parenteral support). The goal is to see if teduglutide can help them reduce or stop the need for these IV treatments.
Hear when a new Short Bowel Syndrome (SBS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.